BioSpace News Archive

Dr. Crystal Brimer, founder of the Dry Eye Institute and owner of Focus Eye Care, Wilmington, NC, is the purchaser of the 2,000th NuLids System sold. NuLids, an innovative doctor-directed, home-use therapy in the fight against dry eye, effectively alleviates symptoms by stimulating and rejuvenating the Meibomian Glands back to a healthier state.

Fresenius Kabi today announced it has received 510(k) clearance from the U.S. Food and Drug Administration for the Fenwal Amicus® Red Blood Cell Exchange (RBCx) system.

Bayer has exercised its option, under a change-in-control clause in the collaboration agreement with Loxo Oncology, to obtain the exclusive licensing rights for the global development and commercialization, for Vitrakvi® (larotrectinib) and BAY 2731954 (LOXO-195).

HOOKIPA Pharma Inc. (“HOOKIPA”), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced the appointment of Michael A. Kelly to the Company’s Board of Directors.

“We’re at an inflection point when it comes to cell and gene therapies. These treatments have the potential to address hundreds of vexing human diseases and conditions.

More than 30 mayors from the Mid-South comprising cities, counties and municipalities across Tennessee, Mississippi and Arkansas spent part of their Valentine’s Day learning more about the critical mission of St. Jude Children’s Research Hospital.

For the second consecutive year, the Medical Advertising Hall of Fame (MAHF) has inducted a key staff member from Chicago agency closerlook, inc.

February is Insurance Careers Month, a cross industry-wide initiative that aims to highlight the wide variety of career paths available in risk management and insurance, as well as support efforts to recruit the next generation of insurance professionals.

Realm Therapeutics plc, a biopharmaceutical company with a proprietary technology platform of stabilized high concentration HOCl, provides an update on its previously announced strategic review.

A new California Workers’ Compensation Institute study finds that non-steroidal anti-inflammatories have supplanted opioids as the most common therapeutic drug group prescribed to injured workers in California, while payment data show that both dermatological medications and anticonvulsants now rank ahead of opioids in terms of total reimbursements.